Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Cardiogenesis
Irvine, California, United Statescardiogenesis.com ↗
- Ownership
- Private
- Employees
- ~30
- Development stage
- Other
01
Overview
Cardiogenesis's core product, an FDA-cleared Ho:YAG laser system for transmyocardial revascularization (TMR), has demonstrated benefits in relieving angina, increasing event-free survival, and improving exercise tolerance in patients not candidates for other reperfusion therapies. The company advanced to include combination strategies pairing TMR with stem cell delivery via its PHOENIX system, showing feasibility and CE mark approval in Europe[2][5][6]. Clinical results include established registry data and peer-reviewed studies showing effective angina relief and improved cardiac outcomes as summarized in registry and clinical trial publications[6][8].
- Therapeutic areas
- Cardiovascular
- Modalities
- DeviceCell therapy
- Industry
- Therapeutic Medical Devices
Beyond the preview
Go deeper on Cardiogenesis.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cardiogenesis.